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Fas Ligand Downregulation with Antisense
Oligonucleotides in Cells and in Cultured Tissues
of Normal Skin Epidermis and Basal Cell Carcinoma
Jingmin Ji, Marion Wernli, Stanislaw Buechner,* and Peter Erb
Fas ligand (FasL), a member of the tumor necrosis factor family, induces apoptosis upon interaction with Fas-receptor-expressing
cells. FasL normally plays an important immune regulatory role, but it can also cause severe skin diseases if overexpressed and it
may serve some tumors for immune evasion. Thus, in situ QJ;inhibition of FasL expression with antisense oligonucleotides in
patients may be a novel approach to overcome its pathogenic role. We designed and evaluated 15 phosphorothioate antisense
oligonucleotides directed against different regions of the human FasL mRNA. They exhibited different inhibitory activities on
FasL expression in HEK293 cells. The most potent antisense oligonucleotide, ASO8, specifically downre-gulated 90% FasL
expression at the protein level and 80% at the mRNA level. FasL downregulation reduced the effector function of HEK293 cells
toward Fas receptor positive target cells. Further studies demonstrated that ASO8 efficiently inhibited FasL synthesis in split skin
and basal cell carcinoma tissue. Our results show that the modulation of FasL expression by antisense oligonucleotides is
possible in cells as well as tissue and indicate that antisense oligonucleotides may provide a promising strategy for the therapy
of FasL-mediated disorders. Key words: basal cell carcinoma/human FasL downregulation/phosphorothioate antisense
oligonucleotide/skin. J Invest Dermatol 120:1094–1099, 2003
Fas ligand (FasL, CD95 ligand), a type II membrane protein, belongs to
the tumor necrosis factor (TNF) family (Suda et al, 1993; Takahashi
et al, 1994). Predominantly expressed in activated T lymphocytes and
natural killer cells, it is also detected in skin epidermis and in immune-
privileged sites such as the eye and testis (Schneider et al, 1997;
Bachmann et al, 2001; D’Alessio et al, 2001). Upon binding to its
receptor Fas, FasL induces apoptosis in Fas-bearing cells. FasL-Fas
interactions play an important role in the elimination of excess cells in
cmbryogenesis, metamorphosis, and tissue turnover, as well as in the
development and regulation of the immune system. FasL-mediated
apoptosis is also important for skin homeostasis (Polakowska et al,
1994; Lee et al, 1998; Bachmann et al, 2001). Kcratinocytes in normal
human skin epidermis constitu-tively express FasL on the plasma
membrane and may induce apoptosis of inflammatory Fasþ cells
entering the epidermis (de Panfilis et al, 2002). The dysregulation of
Fas–FasL interactions may be a key clement in the development of skin
cancer (Hill et al, 1999).
Some skin diseases arc caused by overcxpression of FasL. Kera-
tinocytcs of patients with toxic epidermal necrolysis produce FasL,
which induces apoptosis resulting in the fast destruction of the
epidermis (Viard et al, 1998). Various skin tumors express FasL,
thereby potentially creating their own immunoprivileged sites (Hahne
et al, 1996; Gutierrez-Steil et al, 1998; Lee et al, 1998; Bachmann
et al, 2001). FasL-mediated immune suppression was also proposed in
melanoma (Hahne et al, 1996). In normal melanocytes of the skin no
FasL expression can be detected, but FasL upregulation occurs during
tumorigenesis. The fact that FasL is highly expressed in basal cell
carcinoma (BCC) coincides with the observation that the cells
immediately adjacent to BCC were undergoing apoptosis, whereas T
cells more distant to tumor cells remained viable (Buechner et al,
1997; Gutierrez-Steil et al, 1998). Indeed, FasL-cxpressing melanoma
or BCC cells are able to kill infiltrating Fas T lymphocytes by inducing
apoptosis, thereby escaping the attack of cytotoxic T lymphocytes.
Recently, wc found a similar situation with TRAIL, another member of
the TNF family involved in apoptosis. TRAIL-antisense-expressing
mastocytoma cells demonstrated significantly delayed tumor growth
compared to control cells, as TRAIL downregulation allowed more
macrophages to survive and to better attack the tumor cells (Strebel
et al, 2002). All the available data suggest that the downregulation of
FasL in the above diseases could reduce or eliminate the disorders.
In order to achieve efficient downregulation of FasL expression,
phosphorothioate antisense oligonucleotides (ASO) were applied in
this study. It has been demonstrated that ASO targeting genes involved
in cancer development and progression inhibited cancer cell growth
(Gautschi et al, 2001; Gutierrez-Puente et al, 2002; Lau et al, 2002;
Olie et al, 2002). For example, the clinical studies using Bcl-2
antisense phosphorothioate oligonucleotides gave promising results in
patients with melanoma (Jansen et al, 2000). The antisense strategy may
be particularly well suited for application in skin diseases or in skin
tumors as the skin is easily accessible (Crooke et al, 1996; Wingens et al,
1999; Fimmel et al, 2000). Evaluating a scries of 20-mcr phosphor-
othioatc ASO directed against different regions of the human FasL
mRNA, we selected the most potent ASO and demonstrate that it
efficiently downrcgulates FasL expression not only in cultured cells but
also in human normal split skin and BCC tissue.
MATERIALS AND METHODS
Cells
The human embryonic kidney 293 cells, HEK293-005, stably transfected with a
human FasL-cxpressing plasmid (kindly provided by Dr. Pascal Schneider,
Institute of Biochemistry, University of Lausanne, Switzerland), were cultured in
Dulbccco’s modified Eagle’s nutrient mix (F-12) (Gibco Invitrogen, Basel,
Switzerland) supplemented with 2% fetal bovine scrum (FBS) (Schneider et al,
1997). BALB/c B cell lymphoma A20.2 J (ATCC TIB208) cells stably transfected
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with green fluorescent protein (A20 GFP) were cultured in RPMI 1640 medium
(Gibco Invitrogen) with 5% FBS at 371C in 5% CO2 (Strebel et al, 2001).
Antisense oligodeoxynucleotides
A total of 15 different ASO were designed to target various regions of FasL mRNA
(Accession no. D38122) (Mita et al, 1994; Takahashi et al, 1994), based on the
selection criteria and Mfold program (Zuker, 1989; Smith et al, 2000; Sohail and
Southern, 2000; Lebedeva and Stein, 2001). All ASO were 20-mer long and
phosphorothioatc-modified (Table I); they were synthesized and HPLC-purified by
Europe Gene Scan (Freiburg, German). BLAST search of the NBCI database
revealed no homology of these antisense sequences to any other known human
genes. From ASO8 some shortened analogs (ASO8-2, CTCGG AGTTC TGCCA
GCT; ASO8-4, CGGAG TTCTG CCAGC t; ASO8-6, GAGTT CTGCC AGCT;
ASO8-8, GTTCT GCCAG CT) or mismatched analogs (ASO-2MM, CgCTC tGAGT
TCTGC CAGCT; ASO-4MM, CgCaC tGtGT TCTGC CAGCT; ASO-6MM, CgCaC
tGtGT TgTcC CAGCT) or its sense control (ASO8-sen, AGCTG GCAGA ACTCC
GAGAG) were designed and synthesized in the same way.
Transfection with ASO
HEK293-005 cells were transfected with various concentrations of ASO in the
presence of the carrier Lipofectamine 2000 reagent (Gibco) according to the
manufacturer’s protocol. The transfected cells were cultured at 371C for different
time periods depending on the experiment. The concentrations (nM) of ASO
given in the figures and legends are final concentrations in medium. For tissue
transfection human normal split skin or excised BCC tissue was cut into pieces of
about 1–2mm3. Each piece was transfected with 500 nM ASO8, or its sense
control, or phosphate-buffered saline (PBS) together with Lipofectamine 2000
and cultured in RPMI 1640 medium supplemented with 5% FBS and 0.1mg per
ml gentamicin at 371C in 5% CO2. After 2 d, each piece was transfected again
and cultured for another 2 d.
Flow cytometric analysis
FasL protein expression was stained with mouse antihuman FasL monoclonal
antibody G247-4 (BD) Pharmagen) and analyzed with a FACSCalibur flow
cytometer (Becton-Dickinson, Basel, Switzerland). 10,000–20,000 cells were
investigated. Data were processed with the Cell Quest software (Bachmann et al,
2001).
TaqMan real-time polymerase chain reaction (PCR)
FasL mRNA levels of HEK293-005 cells were determined by quantitative real-time
reverse transcriptase PCR (RT-PCR) in the ABI Prism 7700 Sequence Detection
System (PE Applied Biosystcms, Foster City, CA). At 2 d post-transfection, cells
were collected for isolation of total RNA with RNeasy kit (Qiagen, Basel,
Switzerland). Reverse transcription and RT-PCR were performed as previously
described (Zangemeister-Wittke et al, 2000; Dotsch et al, 2001; Mori et al, 2002).
Human glyccraldchydc-3-phosphate dehydrogenase (GAPDH) mRNA was used as
the internal control. The following primers and TaqMan probes were applied: FasL
sense 50 TGCCT TGGTA GGATT GGGC 30, FasL antisense 50 TCTCG GAGTT
CTGCC AGCTC 30, FasL probe 50 (FAM) ATGTT TCAGC TCTTC CACC (TAMRA)
30; GAPDH sense 50 TCAGC AATGC CTCCT GCAC 30, GAPDH antisense 50 AC
GAT ACCAA AGTTG TCATG GATG 30, GAPDH probe 50 (FAM) AACTG CTTAG
CACCC C (TAMRA) 30.
Functional assay to measure apoptosis induction
At 1.5 d post-transfection with specific ASO8 or its sense control, FasL-
expressing HEK293-005 cells were washed three times with 1PBS and then
cocultured with the Fas-positive apoptosis reporter cells A20 GFP at a ratio of
2:1 (effecter cells:reporter cells) in fluorescence-activated cell sorter (FACS)
tubes overnight. After washing with 1PBS, cells were rcsuspended in 1 PBS
and analyzed by flow cytometry to determine the percentage of apoptotic A20
GFP cells (Strebel et al, 2001).
Immunohistochemistry
Immunohistochcmistry on 6 mm cryosections was done as described earlier
(Bachmann et al, 2001). FasL was stained with mouse antihuman monoclonal FasL
G247-4 (BD Pharmagene, Basel, Switzerland). As isotype control, the same amount
of mouse negative control IgG (Dako Diagnostics, Denmark) was used.
Computer-assisted image analysis quantification
Details of the procedure arc provided elsewhere (Bachmann et al, 2001). In
brief, the immuno-stainings of BCC were digitized. For imaging, the equivalent
gray-level intensity within the region of interest was determined with the
Openlab program (Improvision, Coventry, UK). The mean intensity value of the
isotype control was subtracted from the mean intensity values of the FasL
antibody. For calculation, the subtracted mean values of the measurements
Table I. ASO against human FasL mRNA
ASO Antisense sequences (50 to 30) Target locationa Comments
ASOI TTCTCAGTCC TGTAGAGGCT 125–144 5’ UTR
ASO2 GCCAGCCCCA GCAAACGGTT 152–171 5’ UTR
ASO3 CATGGCAGCT GGTGAGTCAG 172–191 The initiator codon
ASO4 CTGCTGCATG GCAGCTGGTG 178–197 The initiator codon
ASO5 TAATTGAAGG GCTGCTGCAT 189–208 The initiator codon
ASO6 AGTAGATCTG GGGATATGGG 209–228 Coding region
ASO7 TGGGCACAGA GGTTGGACAG 281–300 Coding region
ASO8 CTCTCGGAGT TCTGCCAGCT 517–536 1st splicing site
ASO9 GTGCATCTGG CTGGTAGACT 535–554 1st splicing site
ASO10 CCTATTTGCT TCTCCAAAGA 564–583 2nd splicing site
ASO11 GGGGTGGACT GGGGTGGCCT 581–600 2nd splicing site
ASO12 CCTGTTA A AT GGGCCACTTT 621–640 3rd splicing site
ASO13 CCTTGAGTTG GACTTGCCTG 637–656 3rd splicing site
ASO14 GAATATACAA AGTACAGCCC 747–766 Coding region
ASO15 CTTAGAGCTT ATATAAGCCG 1016–1035 The terminator codon
aAccording to Homo sapiens FasL mRNA, Accession no. D38122.
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obtained from BCC transfected with ASO8 and its sense control were
normalized to the corresponding mock value, which was set to 1.0 (Bachmann
et al, 2001).
RESULTS
Screening for potent ASO that inhibit FasL expression
Although ASO have been widely applied to inhibit the expression of
genes of interest, not all ASO function properly as various ASO
targeting distinct sites on the same mRNA usually express differential
activities. In order to identify the most potent ASO for inhibition of
FasL expression, 15 different ASO, each 20 bases in length and
predicted to hybridize only with FasL mRNA, were synthesized. Two
ASO targeted the 50 untranslated region (50-UTR), three the translation
initiation codon AUG, two targeted each of the three splicing sites,
three the internal coding region, and one ASO targeted the translation
termination site. Table I lists sequences and target locations of all ASO.
The potency of the ASO (250 nm) was assessed by the reduction of
FasL expression in HEK293-005 cells by FACS analysis upon
transfection with Lipofcctaminc 2000. As shown in Fig 1, the inhibitory
activity of the specific ASO varied greatly. ASOS, AS09, and AS013
down regulated FasL expression up to 90%, whereas AS06 and AS015
downregulated FasL by less than 40%. ASO transfccted into cells
without Lipofectamine 2000 did not exhibit any significant inhibition
of FasL expression (data not shown).
The three most active ASO (ASO8, ASO9, and ASO13) all targeted
the first or third splicing sites of FasL mRNA, respectively (Table I). This
indicates that FasL mRNA must contain higher order RNA structures
that limit the accessibility for the other ASO. Thus, the differential
activities of the 15 ASO could be due to different accessibility of the
FasL mRNA. To explore the accessibility of the region surrounding the
target site of AS013, six more ASO were synthesized by shifting the
target sites at both ends of AS013 in increments of three bases. All six
ASO exhibited a similar (but not the same) inhibition of FasL
expression to AS013, but never exceeded the activity of ASOB (data
not shown). Therefore, for the following experiments only ASOH was
used.
ASO8 specifically inhibits FasL expression
Titration experiments with ASOB showed that the ASO-mcdiated
inhibition is concentration dependent (Fig 2A). The higher the
concentration of the ASO used to transfect HEK293 cells, the higher
was the inhibition observed. The median inhibitory concentration IC50
for ASO8 was at 20 nM. Concentrations higher than 500 nM did not
significantly increase the inhibitory potential of the ASO tested.
Moreover, at concentrations higher than 1500 nM the cells tended to
die (data not shown).
To examine the specificity of ASO8, three mismatched analogs
(ASO8-2MM, ASO8-4MM, ASO8-6MM, containing two, four, six
mismatched bases, respectively) and its sense oligonucleotide were
designed and synthesized. The effect of each control ASO on FasL
expression was determined by FACS analysis and the relative
inhibition was normalized to the inhibition of ASO8, which was
set to 1. Figure 2(B) shows that the 2MM analog lost its inhibitory
potential on FasL expression by 70% compared to ASO8, whereas
4MM or 6MM analogs and sense control expressed little
inhibition, indicating that the ASO8-mediated inhibition is sequence
dependent.
In addition, some shortened ASO8 analogs (ASO8-2, ASO8-4,
ASO8-6, and ASO-8, which miss two, four, six, and eight bases at the
50 end of ASO8, respectively) were synthesized and tested. ASO8-6
and ASO8-8 lost most of their inhibitory activity whereas ASO8-2 and
ASO8-4 retained part of the ASO8 antisense activity (Fig 2C). Thus, the
antisense effect of ASO8 on FasL is also dependent on the ASO chain
length. ASO shorter than 14 bases in length lost their activity and ASO
longer than 14 bases demonstrated increasing inhibitory activities with
oligonucleotide chain length. Analogs longer than 20 bases were not
tested, however, as they tend to hybridize to other mRNA molecules
according to BLAST results, decreasing their inhibition specificity.
To evaluate the time kinetics of ASO8, inhibition of FasL expression
was determined by FACS analysis at days 2, 3, 4, 5, 7, and 9 post-
transfection of HEK293-005 cells with 250 nM of ASO8 (Fig 2D).
Although the inhibition level decreased gradually from day to day, more
than 70% of FasL expression was still inhibited by ASO8 at day 4. On
day 9, the remaining inhibition was about 20% of the original level.
To confirm the inhibition of FasL expression by ASO8 at the mRNA
level, total RNA was purified from the transfccted cells. FasL mRNA
expression was determined by quantitative real-time RT-PCR simulta-
neously with GAPDH as internal control (Fig 2E). ASO8 down-
regulated FasL mRNA expression by 80%, whereas its sense control
did not cause any inhibition.
ASO8 inhibits the apoptosis-inducing function of FasL
It was tested whether downregulation of FasL in HEK293-005 cells
with ASO8 also downregulated their effector function towards Fas-
expressing A20 GFP cells. Figure 3 demonstrates that more than 60%
A20 GFP cells survived when cocultured with ASO8-transfccted
HEK293-005 cells, in contrast to about 90% of A20 GFP cells that
became apoptotic upon coculture with sensc-control-transfected
HEK293-005 cells or with PBS-treated HEK293-005 cells. The reason
why some A20 GFP cells (E40%) still became apoptotic upon
coculture with ASO8-transfected HEK293-005 effector cells is that
ASO8 did not completely downrcgulatc FasL on all cells and a few
effector cells may even not have been transfccted at all. In any case,
the data demonstrate that downregulation of FasL protein expression
on HEK293 cells by ASO8 substantially inhibits their effector function
against Fasþ target cells.
ASO8 inhibits FasL expression in cultured split skin
In normal skin epidermis the basal layer and to a lesser extent also the
upper layers express FasL (Bachmann et al, 2001). It is thought that
FasL serves as an important sensor in the epidermis to preserve skin
integrity (Polakowska et al, 1994; Hill et al, 1999). Furthermore, we
wanted to know whether the FasL antisense strategy also works in
tissue, e.g., skin epidermis. As tissue, split skin was used, which was
cut into small pieces and cultured with 500 nM ASO8 or its sense
control and the corresponding concentration of Lipofectamine 2000.
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Figure 1. Evaluation of the inhibitory potential of different ASO. HEK293
cells were transfected with different ASO (ASO1 to ASO15, each with 250 nM)
or with PBS in the presence of Lipofectamine 2000. At 2 d post-transfection,
the extracclluar FasL expression was determined by FACS analysis using
specific anti-FasL monoclonal antibody G247-4. Results were expressed as
the mean of triplicate experiments±SD.
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In order to make the ASO accessible to as many cells as possible within
the tissue, the transfection was repeated after 2 d. Two days later
cryosections were made and analyzed by immunohistochemistry with
mouse antihuman specific FasL monoclonal antibody G247-4. Figure 4
shows that ASO8 strongly downregulated FasL expression in split skin
(Fig 4B), whereas the sense control did not (Fig 4C), indicating that
ASO8 inhibits FasL expression not only in single cells but also in tissue.
ASO8 inhibits FasL expression in BCC
BCC is the most frequent skin tumor in Caucasians and its incidence is
still rising. Strong FasL expression is detected in BCC and believed to
be crucial for their expansion (Gutierrez-Steil et al, 1998). Down-
regulation of FasL expression in BCC may allow immune effector cells
to attack and kill BCC in patients. In this study, we addressed the
question whether specific ASO might inhibit FasL expression in BCC
tissue in vitro. BCC were treated with ASO8 and control similarly to
split skin. Figure 5 demonstrates that ASO8 efficiently inhibited FasL
expression (Fig 5B), whereas the sense control did not (Fig 5C),
showing a similar FasL expression as in the control (Fig 5A). FasL
expression was quantitated by computer-assisted image analysis
Figure 2. ASO8 specifically downregulates FasL expression. ASO8 specifically downrcgulatcs FasL expression in a concentration-dependent (A), sequence-
dependent (B), nucleotidc-lcngth-dependent (C), and time-dependent (D) manner, as well as at the mRNA level (E). For dose–response evaluation HEK293 cells
were transfected with different concentrations (5, 10, 20, 50, 100, 200, 200, 500 nM) of ASO8 in the presence of Lipofcctamine 2000; for all other conditions
250 nM ASO8 or controls were used. FasL protein expression was determined by FACS analysis at 2 d post-transfection or at the times given in the figure (D). The
relative inhibition was normalized to the inhibition of ASO8, which was set to 1 (B, C). FasL mRNA level was determined by quantitative real-time RT-PCR
simultaneously with GAPDH internal control and normalized accordingly (E). Results are expressed as the mean of two experiments±range.
Figure 3. Functional assay for FasL. A20 GFP cells were cultured overnight
alone or with HEK293 cells transfccted with 250 nM ASO8, its sense control,
or PBS. The percentage of apoptotic A20 cells was then determined by FACS
analysis. Results are expressed as the mean of two experiments±range.
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(Fig 5D), showing that ASO8 but not the sense control downregulated
FasL expression in BCC tissue up to 70%.
DISCUSSION
This study demonstrates that rationally selected, specific phos-
phorothioate ASO efficiently deactivate the human FasL gene as
shown by the downrcgulation of FasL expression in cultured cells. The
optimally active ASO targeted the first or third splicing sites of the FasL
mRNA, had a length of 20 bases, and specifically inhibited FasL
expression in a broad range of concentration applied for at least 4 d.
Further investigation of the most potent ASO, ASO8, showed that it
functioned efficiently not only in cultured cells but also in tissues, i.e.,
normal skin and a skin tumor, the BCC. Our data support the
observation that human skin is easily accessible for phosphorothioate
ASO (Wingens et al, 1999; Wraight and White, 2001).
Functionally, the downrcgulation of FasL expression resulted in a
markedly reduced apoptosis-inducing potential of the Fas-expressing
cells. Although FasL is assumed to function as an important sensor in
normal skin epidermis (Polakowska et al, 1994; Bachmann et al,
2001), its role in tumor cells seems to be different (Gutierrez-Steil et al,
1998). Published data support the concept that FasL-expressing tumor
cells can evade immune surveillance by killing Fas-expressing effector
cells (Hahne et al, 1996; O’Connell et al, 1996; Bennett et al, 1999;
Gutierrez et al, 1999). Recently, it was shown in a mouse model that
the transfection of FasL-antisense-expressing plasmid DNA into tumor
tissue downrcgulated FasL translation in the tumor cells, and inhibited
tumor progression by approximately 50% compared with the control
group, strongly indicating that the FasL-mediated tumor counter-attack
was impaired (Nyhus et al, 2001). Therefore, selective inhibition of
FasL gene expression in tumor cells with ASO could be an efficient
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Figure 4. Specific ASO inhibit FasL expression in human split skin. Human normal split skin was cut into small pieces. Each of them was transfected with
500nM ASO8 (B), its sense control (C), or PBS (A) and cultured for 2 d. The transfection was then repeated and the split skin was cultured for another 2 d. Cryosections
were made and stained with monoclonal anti-FasL G247-4 or isotype control. Sections are representative of three different split skins. Scale bar. 15mm.
Figure 5. Specific ASO inhibit FasL expression in human BCC. BCC was cut into small pieces. Each of them was transfected as described in the legend to Fig 4.
Cryosections were prepared from BCC treated with PBS (A), ASOS (B), or its sense control (C) and immunostained with mouse monoclonal antihuman FasL
G247-4. Strong FasL expression is seen on the cell membrane (arrows) in the PBS and sense control sections, but not in the ASO8 section. Scale bar. 15 mm. To
quantitate the downrcgulation of FasL expression, computer-assisted image analysis was performed (D). The mean intensity value of isotype control was
subtracted from those of monoclonal FasL G247-4. Relative gray scale indexes (mean±SD) are compared to the mean value of the PBS control, which was set
to 1. Ten measurements were made in five different sections. BCC obtained from three patients were investigated.
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local pharmacologic approach to diminish the tumor0s immune
privilege.
Current treatment of BCC is by surgery or by the intralcsional
application of interferon-a (IFN-a) (Buechner et al, 1997; Bower et al,
2001). Upon treatment with IFN-a the Fas-negative but FasL-positivc
BCC start to express Fas and the tumor cells become apoptotic, most
probably due to Fas–FasL interaction (Buechner et al, 1997). Thus,
upregulation of Fas successfully leads to tumor regression. Recently, it
has been shown that Fas and FasL are significantly increased during
photodynamic-therapy-mediated apoptosis in human epidermoid
carcinoma A431 cells (Ahmad et al, 2000). Alternatively, down
regulation of FasL may also lead to tumor regression as the tumor cells,
now lacking the protective molecule for immune evasion, may
become susceptible to the attack of immune effector cells. This
hypothesis will now be testable not only because BCC of the skin are
easily accessible but also due to the fact that ASO can be effectively
transfected into tissues. If the hypothesis turns out to be correct, other
FasL-expressing tumors can also be tried as targets for such an ASO
approach, e.g., squamous cell carcinoma and melanoma. Both tumors
express FasL, and in analogy to BCC the major role of FasL is proposed
to be to mediate immune evasion. The therapeutic use of ASO is
feasible. Indeed, various therapeutic applications based on ASO are
already in clinical trials (Wingens et al, 1999; Wraight and White,
2001; Nedbal and Tcichmann, 2002) and the first ASO drug
(Vitravene) has been approved by the FDA, clearly implying that
ASO have therapeutic prospects.
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